PubMed Health⌕ Search

Biomedical subjects

R Waśko

Publications and source records attributed to R Waśko.

15 recordsLinked to original sources
PubMed2006

Ghrelin ovarian cell expression in patients with polycystic ovary syndrome: an immunohistochemical evaluation.

INTRODUCTION: The influence of ghrelin on different organs has been studied recently, e.g. in the regulation of pituitary hormone release, regulation of energy homeostasis, glucose metabolism and insulin secretion, cell proliferation, and reproductive function. However, the etiology of polycystic ovary syndrome has not been fully explained. The aim of our study was to estimate the presence of ghrelin in polycystic ovaries cells and evaluation of the relationship between ghrelin occurrence and cells proliferation. METHODS: In the present work we have compared ten polycystic ovaries with ovaries without pathology as the control group. We used immunohistochemical method to detect ghrelin. The cells proliferation was evaluated by Ki 67 proliferation index. RESULTS: Ghrelin immunostaining was demonstrated in cytoplasm of ovarian secondary interstitial cells and in atretic corpus luteum. The cell nuclei were ghrelin positive in granulosa, theca layers of follicular cyst in both groups as well as in luteal cells of young corpus luteum in healthy ovaries. Ki 67 immunostaining was observed in granulosa and theca layers of follicular cyst in polycystic and healthy ovaries. CONCLUSIONS: It is possible that local ghrelin expression plays an important role in the direct control of ovarian development and function and ghrelin may participate in patomechanism of PCOS.

Adolescent↗
PubMed2004

Elevated ghrelin plasma levels in patients with polycystic ovary syndrome.

Polycystic ovary syndrome is a common endocrine disorder in women. It is associated with hirsuitism, obesity, insulin resistance, abnormality in the growth hormone/insulin-like growth factor I (IGF-1) axis and polycystic ovaries. The etiology of PCOS has not been clarified. Ghrelin is an endogenous ligand of the growth hormone secretagogue receptor. It is mainly secreted by stomach cells but has also been shown to be present in hypothalamus, pituitary, pancreas and gonads. Ghrelin is a regulator of energy homeostasis and GH secretion. The influence of ghrelin on insulin secretion and gonadal function is known. Since ghrelin may play an important role in pathophysiology of PCOS, we studied ghrelin levels in a group of 52 women with PCOS and in 16 women in a control group. Plasma levels of insulin, total testosterone, SHBG, LH, and FSH were also measured. In conclusion, PCOS women have higher ghrelin levels than controls. Ghrelin negatively correlates with BMI and insulin levels in PCOS group. A relation between ghrelin and SHBG was observed. Our data suggest that ghrelin could be the possible link in PCOS etiology.

Adolescent↗
PubMed2001

[Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].

Acromegaly is caused by excessive secretion of growth hormone by a hypophyseal adenoma type of somatotropinoma. IGF-I is formed in the liver and mediates most biological actions of GH. Treatment of adenomas, which secrete GH, involves pharmacotherapy followed by surgery. Modern pharmacotherapy leaning is based on somatostatin analogues (factor restrictive secretion GH): octreotide, octreotide LAR and lanreotide. The aim of our study was estimation of efficiency of octreotide LAR in the patients with somatotropinoma prepared to neurosurgery intervention. We examined 16 patients (10 of women and 6 men) with the features of active acromegaly. In all cases the increased concentration of HGH and IGF-I were observed. The presence of pituitary adenoma in all patients was confirmed by MRI. The patients were treated with octreotide LAR monthly in dose 20 mg and 30 mg respectively. Before and after application of somatostatin analogues the concentration HGH, IGF-I, PRL in serum were marked. The concentration of GH before octreotide LAR therapy in all patients increased remarkable and ranged from 15.6 to 78.6 ng/ml, mean: 31.20 +/- 16.84 (norm: 0-10 ng/ml), also, in all cases the serum IGF-I level was increased and ranged from 451 to 1107.6 ng/ml, mean: 801.75 +/- 207.82 (norm: 100-400 ng/ml). The prolactin concentration ranged from 7.4 to 49.9 ng/ml, mean: 22.8 +/- 13.7 (norm: 2-20 ng/ml) and in 8 (50%) cases the increased of PRL concentration in serum was observed. After the administration of octreotide LAR the level of: GH [mean: 12.99 +/- 17.16 ng/ml (p < 0.001)], of IGF-I [mean 422.8 +/- 229 ng ml (p < 0.01)] statistical important decreased and prolactin in 8 with increased concentration [mean: 12.45 +/- 5.57 (p < 0.01)] were observed. Long acting somatostatin analogues--octreotide LAR is particular efficient in lowering of growth hormone and IGF-I in patients with somatotropinoma and shows efficiency in normalization of increased prolactin concentration. Because of extreme effectiveness of octreotide LAR, it should be used the routine treatment at the patients suffering from active acromegaly and preparing to neurosurgical treatment.

Acromegaly↗
PubMed2000

Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.

Eighteen patients with symptoms of active acromegaly were treated with somatostatin analogues for 4 weeks before surgery. Both before and after the treatment, levels of growth hormone (GH), prolactin (PRL), insulin growth factor -I (IGF-I), luteotropin (LH), folliculostimulin (FSH) and subunit alpha of glycoprotein hormones were estimated. Glucose tolerance test, magnetic resonance imaging (MRI) examination, sight acuity and field of vision tests were also performed. The same tests were performed on ten control patients with clinically and biochemically active acromegaly, subjected to surgery but not treated with somatostatin analogues. In six patients treated with somatostatin analogues GH levels decreased significantly to less than 5 ng/ml and in two patients remained elevated while in 10 patients GH level decreased and ranged from 6.1 to 42.9 ng/ml. In 13 patients we observed a decrease in IGF-I to normal levels (<400 ng/dl) and in 3 patients we noted a decrease to levels slightly higher than normal. There was also a slight decrease in alpha subunit concentration. In the glucose inhibition test 4 patients demonstrated normalized GH levels. In patients with elevated PRL and TSH levels, treatment with somatostatin analogues induced their decrease. No changes were observed in levels of LH and FSH. After therapy MRI examination disclosed a decrease in tumor volume in two patients (by 20 and 25%, respectively) and no changes in tumor size in 16 patients. The two patients with a decreased tumor volume also showed normalized glucose tolerance tests. All patients manifested an improved clinical condition. Neurosurgeons disclosed a decreased tumor consistency which greatly facilitated surgical procedure. Our studies documented favourable effects of somatostatin analogues on the assayed hormone levels, and on the general condition of the patients as well as on the course of the surgical procedure itself.

Acromegaly↗
PubMed1997

[Investigations on the pathogenesis of primary varicose veins].

The data from the clinical course and epidemiology of primary varicose veins of lower limb suggest that sex hormones can directly influence the development of the disease through their intracellular receptor localised in cells of venous wall. The purpose of this study was to determine the stereometric differences in the structure of healthy and varicose veins of lower limb and to determine the presence and localisation of oestrogen and progesterone receptors in the cells of vein. The segments of greater saphenous vein obtained from the 8 women operated for varicose vein were used for the study. The segments of the greater saphenous vein obtained from 8 women that underwent femoro-popliteal venous bypass procedure were used as control group. The vein samples for stereometric analysis were preserved in Buin's solution, embedded in paraffin and then evaluated with automatic analyser MagiCal. To determine the presence of oestrogen and progesterone receptors the immunohistochemic analysis LAB with monoclonal antibodies produced by DAKO was used. The decreased smooth muscle fraction in venous wall, thickening of adventitia, the change of the smooth muscle cells to stroma cells ratio in the muscular layer of venous wall and change of muscular layer to adventitia ratio were observed in varicose veins in comparison with control group. The oestrogen receptors were found in the nuclei of the smooth muscle cells and endothelium. The progesterone receptors were localised in nuclei of smooth muscle cells and cells of subendothelial layer. It seems that quantitative analysis of sex hormones receptor in the venous wall could be useful in the determination of patients with increased risk of the development of primary varicose veins.

Female↗
PubMed1996

[Radioimmunologic methods for determining cortisol binding globulin-CBG in human serum].

The authors described double antibodies radioimmunoassay of human cortisol binding globulin serum level in support of previous isolated and purified trancortin and anti-transcortin antibodies produced by rabbit immunization. Antigen was iodinated by chloraminet method and purification on Ultragel AcA 54 column. Standard curve had specific Bx/Box100%. Using described method investigation of transcortin globulin serum level is precise and repetitive.

Carrier Proteins↗
PubMed1994

[Synthesis and characteristics of anti-CBG antibodies (anti-transcortin)].

We used corticosteroid binding globulin purified by chromatography on the Sepharose column for immunisation of the rabbits. We analysed serum by rocket immunoelectrophoresis and cross immunoelectrophoresis. The titre of the serum was estimated by reaction with 125 I-labelled transcortin (corticosteroid binding globulin). The results of our studies indicate that own serum is valuable and can be use for radioimmunoassay of the CBG in the serum.

Animals↗
PubMed1994

[Isolation and purification of transcortin (cortisol binding globulin--CBG) using two-step chromatography].

The isolation of cortisol and progesterone binding globulin (CBG) from pregnant women serum was performed using affinity and hydrophobic chromatography. The purity and specificity of isolated transcortin was tested by agarose gel electrophoresis using racket and cross immunoelectrophoresis and specific CBG antibodies. High purity and immunoreactivity of the isolated globulin destitute of other proteins contamination, were obtained.

Chromatography↗
PubMed1989

[Changes in serum levels of glycoprotein hormone alpha subunits in patients with alphoma-type pituitary tumors during LHRH and TRH stimulation tests].

A group of 21 patients with the alphoma-type pituitary tumors was studied. In 9 cases the tumor was associated with acromegaly. Alpha subunit concentration was determined in all the patients and in control subjects in the course of dynamic tests consisting in simultaneous intravenous administration of 200 micrograms TRH and 100 micrograms LH-RH. In basal conditions the concentration of alpha subunit in patients with the alphoma-type tumors ranged between 2.1 and 30 micrograms/l (mean 7.5 +/- 6.6 micrograms/l), and in controls the respective values ranged between 0.2 and 1.6 micrograms/l (mean 0.78 +/- 0.36 micrograms/l). In the course of the LH-RH + TRH test there was an increase in the alpha subunit level both in the patients with alphoma associated with acromegaly and in the remaining cases of alphoma. Statistical analysis of the results obtained for the whole group of patients revealed a significant linear correlation between the alpha unit concentration 20, 30, 60 and 90 minutes following stimulation with the neurohormones and that before stimulation. For 9 patients with the acromegaly-associated tumors a statistically significant increase in the alpha subunit concentration was noted only at the 90-th minute of the stimulation test, while for the remaining 12 patients with alphoma an increase was statistically significant for the whole time of the duration of the test. In healthy subjects the concentration of alpha subunit never exceeded the limits of the normal values in the course of the LH-RH + TRH stimulation test.

Adenoma↗
PubMedDate not supplied

[Glycoprotein hormone alpha subunit as a marker of pituitary adenoma].

Blood serum FSH, LH, prolactin and testosterone as well as urinary excretion of 17KS and 17-OHCS were determined in 8 patients with chromophobe pituitary adenomas treated by transphenoidal microsurgical removal or craniotomy with or without subsequent telecobalt therapy. It was found te disease tends to recur in the majority of patients despite the type of therapy. Recurrence is accompanied by gonadotropins hyposecretion, increase in prolactin secretion, secretory disorders in the gonads and adrenals; an increase in prolactin secretion is proportional to the intensity of the compression symptoms. Bromocriptine in a daily doses ranging from 5.0 to 7.5 mg decreases prolactin levels in the recurrent chromophobe pituitary adenomas and does not affect their proliferation.

Adenoma, Chromophobe↗